Cantor Fitzgerald Has Weak Estimate for ITCI FY2025 Earnings

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) – Equities researchers at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for Intra-Cellular Therapies in a research report issued on Monday, February 24th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will post earnings per share of ($0.51) for the year, down from their prior forecast of ($0.25). Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Intra-Cellular Therapies’ current full-year earnings is ($0.64) per share.

ITCI has been the topic of several other research reports. Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $140.00 to $132.00 in a research note on Monday. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their target price for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. StockNews.com started coverage on shares of Intra-Cellular Therapies in a research report on Monday. They issued a “hold” rating on the stock. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Finally, Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Ten investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $106.08.

Intra-Cellular Therapies Trading Down 0.2 %

ITCI stock opened at $128.25 on Wednesday. The stock has a 50-day moving average price of $112.80 and a two-hundred day moving average price of $90.87. The company has a market cap of $13.64 billion, a PE ratio of -147.41 and a beta of 0.72. Intra-Cellular Therapies has a 12-month low of $63.30 and a 12-month high of $129.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million.

Hedge Funds Weigh In On Intra-Cellular Therapies

Several institutional investors and hedge funds have recently modified their holdings of ITCI. GF Fund Management CO. LTD. acquired a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth about $186,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Intra-Cellular Therapies by 3.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 335,319 shares of the biopharmaceutical company’s stock valued at $28,006,000 after acquiring an additional 12,111 shares during the period. Two Sigma Advisers LP acquired a new stake in Intra-Cellular Therapies during the fourth quarter worth approximately $11,966,000. Two Sigma Investments LP boosted its holdings in shares of Intra-Cellular Therapies by 507.9% during the fourth quarter. Two Sigma Investments LP now owns 142,791 shares of the biopharmaceutical company’s stock worth $11,926,000 after acquiring an additional 119,301 shares during the period. Finally, Tidal Investments LLC grew its position in shares of Intra-Cellular Therapies by 4.5% in the fourth quarter. Tidal Investments LLC now owns 5,027 shares of the biopharmaceutical company’s stock valued at $420,000 after purchasing an additional 215 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Sharon Mates sold 51,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. This represents a 4.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 2.60% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.